右美托咪定对脓毒症机械通气患者死亡率及无呼吸机天数的影响:一项随机临床试验
这项在日本8个重症监护病房开展的开放标签多中心随机临床试验,纳入201例需机械通气至少24小时的脓毒症成人患者,比较右美托咪定镇静与无右美托咪定镇静。结果显示两组28天死亡率与28天内无呼吸机天数均无显著差异,右美托咪定组镇静控制良好比例显著更高。
要点
- 右美托咪定组与对照组28天死亡率无显著差异(22.8% vs 30.8%;HR 0.69;95%CI 0.38-1.22;P=.20)。
- 28天内无呼吸机天数两组无显著差异(中位数20天 vs 18天;P=.20)。
- 右美托咪定组机械通气期间镇静控制良好比例显著更高(范围17%-58% vs 20%-39%;P=.01)。
核心结论
- 在需机械通气的脓毒症患者中,使用右美托咪定与不使用右美托咪定相比,未在死亡率或无呼吸机天数上带来统计学显著改善。
- 作者指出该研究对死亡率的检验可能把握度不足,可能需要进一步研究来评估。
研究设计与样本
- 开放标签、多中心随机临床试验,在日本8个重症监护病房开展,时间为2013年2月至2016年1月。
- 纳入201例需机械通气至少24小时的连续成人脓毒症患者,随机分为右美托咪定镇静组(n=100)和无右美托咪定镇静的对照组(n=101)。
- 两组其他用药包括芬太尼、丙泊酚和咪达唑仑。
主要发现
- 28天死亡率右美托咪定组为19例(22.8%),对照组为28例(30.8%);风险比0.69;95%CI 0.38-1.22;P=.20,无显著差异。
- 28天内无呼吸机天数右美托咪定组中位数20天(四分位距5-24天),对照组中位数18天(四分位距0.5-23天);P=.20,无显著差异。
- 右美托咪定组机械通气期间镇静控制良好比例显著更高(范围17%-58% vs 20%-39%;P=.01)。
- 其他次要结局两组间无显著差异。
- 不良事件右美托咪定组发生8例(8%),对照组发生3例(3%)。
局限性
- 作者指出该研究对死亡率的检验可能把握度不足。
- 作者指出可能需要进一步研究来评估右美托咪定对脓毒症机械通气患者死亡率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dexmedetomidine provides sedation for patients undergoing ventilation; however, its effects on mortality and ventilator-free days have not been well studied among patients with sepsis. OBJECTIVES: To examine whether a sedation strategy with dexmedetomidine can improve clinical outcomes in patients with sepsis undergoing ventilation. DESIGN, SETTING, AND PARTICIPANTS: Open-label, multicenter randomized clinical trial conducted at 8 intensive care units in Japan from February 2013 until January 2016 among 201 consecutive adult patients with sepsis requiring mechanical ventilation for at least 24 hours. INTERVENTIONS: Patients were randomized to receive either sedation with dexmedetomidine (n = 100) or sedation without dexmedetomidine (control group; n = 101). Other agents used in both groups were fentanyl, propofol, and midazolam. MAIN OUTCOMES AND MEASURES: The co-primary outcomes were mortality and ventilator-free days (over a 28-day duration). Sequential Organ Failure Assessment score (days 1, 2, 4, 6, 8), sedation control, occurrence of delirium and coma, intensive care unit stay duration, renal function, inflammation, and nutrition state were assessed as secondary outcomes. RESULTS: Of the 203 screened patients, 201 were randomized. The mean age was 69 years (SD, 14 years); 63% were male. Mortality at 28 days was not significantly different in the dexmedetomidine group vs the control group (19 patients [22.8%] vs 28 patients [30.8%]; hazard ratio, 0.69; 95% CI, 0.38-1.22; P = .20). Ventilator-free days over 28 days were not significantly different between groups (dexmedetomidine group: median, 20 [interquartile range, 5-24] days; control group: median, 18 [interquartile range, 0.5-23] days; P = .20). The dexmedetomidine group had a significantly higher rate of well-controlled sedation during mechanical ventilation (range, 17%-58% vs 20%-39%; P = .01); other outcomes were not significantly different between groups. Adverse events occurred in 8 (8%) and 3 (3%) patients in the dexmedetomidine and control groups, respectively. CONCLUSIONS AND RELEVANCE: Among patients requiring mechanical ventilation, the use of dexmedetomidine compared with no dexmedetomidine did not result in statistically significant improvement in mortality or ventilator-free days. However, the study may have been underpowered for mortality, and additional research may be needed to evaluate this further. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01760967.
引用
- Kawazoe Y, Miyamoto K, Morimoto T, et al. Effect of Dexmedetomidine on Mortality and Ventilator-Free Days in Patients Requiring Mechanical Ventilation With Sepsis: A Randomized Clinical Trial. JAMA. 2017. PMID: 28322414. doi:10.1001/jama.2017.2088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。